Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: Study protocol

Định dạng: pdf / Số trang: 8

Nhắn tin với admin nếu không tải được